INTERLEUKIN-6 TRANS-SIGNALLING INHIBITION WITH OLAMKICEPT (SGP130FC) IN ACTIVE IBD RESULTS IN EARLY UNIQUE MOLECULAR SIGNATURES PREDICTING CLINICAL REMISSION AND DIFFERENTIATING FROM REMISSION INDUCTION BY VEDOLIZUMAB OR INFLIXIMAB

olamkicept (FE999301) - Ferring

Remicade (infliximab) - Mitsubishi Tanabe, J&J

Entyvio (vedolizumab) - Takeda

https://www.professionalabstracts.com/ueg2019/Iplanner/#/presentation/1273

Aden K.1; Conrad C.2; Bernardes J.P.3; Tran F.4; Hoeper H.3; Sommer F.3; Nikolaus S.5; Lokau J.6; Garbers C.6; Rose-John S.7; Röcken C.8; Waetzig G.H.9; Rosenstiel P.10; Schreiber S.11

Aug 18, 2019